Updates are available Correction dated 2024-10-18
Click to view Correction: https://doi.org/10.1038/s41409-024-02435-8
-
Authors
Penack, Olaf https://orcid.org/0000-0003-4876-802X
Peczynski, Christophe https://orcid.org/0000-0002-3829-0088
Boreland, William https://orcid.org/0009-0007-9739-0816
Lemaitre, Jessica
Reinhardt, H. Christian
Afanasyeva, Ksenia
Avenoso, Daniele https://orcid.org/0000-0003-4218-4170
Holderried, Tobias A. W. https://orcid.org/0000-0002-2474-523X
Kornblit, Brian Thomas
Gavriilaki, Eleni https://orcid.org/0000-0002-8883-8208
Martinez, Carmen https://orcid.org/0000-0002-8401-7306
Chiusolo, Patrizia https://orcid.org/0000-0002-1355-1587
Mico, Maria Caterina
Daguenet, Elisabeth https://orcid.org/0000-0002-6101-1016
Wichert, Stina
Ozdogu, Hakan https://orcid.org/0000-0002-8902-1283
Piekarska, Agnieszka
Kinsella, Francesca https://orcid.org/0000-0002-6022-2567
Basak, Grzegorz W. https://orcid.org/0000-0003-3858-8180
Schoemans, Hélène https://orcid.org/0000-0002-7568-8239
Koenecke, Christian https://orcid.org/0000-0001-7025-1735
Moiseev, Ivan https://orcid.org/0000-0002-4332-0114
Peric, Zinaida
- License Information
-
More Information
Article History
Received: 24 August 2023
Revised: 13 November 2023
Accepted: 1 December 2023
First Online: 6 January 2024
Change Date: 11 October 2024
Change Type: Update
Change Details: The original online version of this article was revised: In this article the author name Daguenet has been misspelled and affiliated incorrectly. These have been corrected.
Change Date: 18 October 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41409-024-02435-8
Competing interests
: The study was funded by Mallinckrodt Pharmaceuticals. OP has previously received honoraria from Mallinckrodt Pharmaceuticals, but not for the current project. OP has received honoraria or travel support from Gilead, Jazz, MSD, Novartis and Pfizer. He has received research support from Incyte and Priothera. He is member of advisory boards to Equillium Bio, Jazz, Gilead, Novartis, MSD, Omeros, Priothera, Sanofi, Shionogi and SOBI. TAWH has previously received honoraria or travel support from Mallinckrodt Pharmaceuticals and Novartis, but not for the current project. <i>Honoraria</i>: Amgen, Bristol-Myers-Squibb, GlaxoSmithKline, Jazz; <i>Consulting or advisory role</i>: Amgen, Jazz, Kite/Gilead, Novartis, Sanofi, Bristol-Myers-Squibb, Pfizer, GlaxoSmithKline; <i>Travel, accommodation, expenses</i>: Janssen, Jazz, Abbvie, Bristol-Myers-Squibb, Amgen, Kite/Gilead, Astellas, Neovii, GlaxoSmithKline, Sanofi, Mallinckrodt. HS reports having received personal fees from Incyte, Janssen, Novartis, Sanofi and from the Belgian Hematological Society (BHS), as well as research grants from Novartis and the BHS, all paid to her institution. She has also received non-financial support (travel grants) from Gilead, Pfizer, the EBMT and the CIBMTR. IM has received honoraria from Novartis, Johnson & Johnson, Sanofi. FK has received honoraria from Mallinckrodt (but not for this project), Sanofi and research funding from Gilead. PC FK has received honoraria from Mallinckrodt (but not for this project). EG has received honoraria or research support from Astra Zeneca, Gilead, Jazz, Omeros, Sanofi and Sobi Pharmaceuticals. The remaining authors declare no conflict of interests.
